News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Subscribe To Our Newsletter & Stay Updated
